SUNDAY, JULY 15, 2018

ABL collaborates with RDI on HIV Treatment Response Prediction System

Advanced Biological Laboratories (ABL) S.A. will collaborate with the HIV Resistance Response Database Initiative (RDI) on a project to enhance HIV patient management.

The first step of the collaboration resulted in the uploading of ABL's TherapyEdge health management system to RDI's HIV Treatment Response Prediction System (HIV-TRePS).

HIV-TRePS uses data form tens of thousands of patients to estimate how successful any combination of antiretroviral drugs will be. The program will be enhanced through its partnership with TherapyEdge, which is a patient management system that assimilates data from healthcare professionals caring for people with chronic diseases that may be life threatening.

"We are very pleased to be collaborating with RDI to enhance physicians' access to HIV-TRePS," Chalom Sayada, the CEO of ABL, said. "Studies suggest the system can help physicians avoid failing regimens and even reduce costs, so facilitating its use as part of our patient management system could bring significant patient benefits."

Over the last 12 years, the RDI has developed the world's largest database for HIV drug resistance and treatment outcome data.

"This is an exciting and highly logical step forward capitalizing on the complementarity of our systems in a way that I believe is a model for the future management of many different medical conditions," Brendan Larder, the scientific chair of the RDI, said. "We are hopeful that the collaboration will also accelerate the collection of outcome data and enable us to develop new and further improved versions of HIV-TRePS."